<DOC>
	<DOCNO>NCT00111111</DOCNO>
	<brief_summary>The purpose multicenter , open-label , prospective study evaluate effectiveness safety etanercept treatment subject psoriasis .</brief_summary>
	<brief_title>An Evaluation Etanercept Treatment Subjects With Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Stable , active plaque psoriasis involve great equal 10 % body surface area ( BSA ) screen baseline Any grade 3 4 adverse event infection within 28 day screen , screen visit study drug initiation Evidence skin condition ( e.g. , eczema ) psoriasis would interfere evaluation effect study medication psoriasis Psoralen plus ultraviolet A radiation ( PUVA ) , oral retinoids , cyclosporine , alefacept ( Amevive® ) , efalizumab ( Raptiva® ) , systemic antipsoriasis therapy within 28 day study drug initiation Ultraviolet light B ( UVB ) therapy , topical steroid , topical vitamin A D analog preparation , anthralin within 14 day study drug initiation ( exception : topical steroid , high moderate strength , permit scalp , axilla , groin dose formulation must remain stable throughout trial ) Prior exposure tumor necrosis factor ( TNF ) inhibitor , include etanercept Severe comorbidities Known history tuberculosis ( TB ) , previous positive purify protein derivative ( PPD ) test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>